WAM
CHRS icon

Wolverine Asset Management’s Coherus Oncology CHRS Stock Holding History

Wolverine Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,700
Closed -$21.3K – 1821
2023
Q3 		$21.3K Sell
5,700
-3,100
-35% -$14.3K ﹤0.01% 1353
2023
Q2 		$37.6K Buy
8,800
+8,700
+8,700% +$51.3K ﹤0.01% 1208
2023
Q1 		$684 Sell
100
-9,000
-99% -$69.8K ﹤0.01% 1738
2022
Q4 		$72.1K Buy
+9,100
New +$70K ﹤0.01% 1332
2021
Q4 		– Sell
-1,400
Closed -$22K – 2070
2021
Q3 		$22K Hold
1,400
– – ﹤0.01% 1607
2021
Q2 		$19K Buy
+1,400
New +$19.8K ﹤0.01% 1914

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wolverine Asset Management's CHRS Position: Q1 2024 in Review

Wolverine Asset Management sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 2,573 shares — an estimated $8.57K sold.

Wolverine Asset Management first reported a position in CHRS in Q3 2023 and held it in 2 quarters. The position peaked at $30.9K in Q3 2023. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

  • Wolverine Asset Management reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
  • Wolverine Asset Management sold 2,573 Coherus Oncology shares in Q1 2024, an estimated $8.57K.
  • Wolverine Asset Management first reported a position in Coherus Oncology in Q3 2023 and held it in 2 quarters.
  • Wolverine Asset Management's Coherus Oncology position peaked at $30.9K in Q3 2023.
  • 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Wolverine Asset Management's 13F filing for Q1 2024, filed 13 May 2024.